Details of person submitting  
NameMarcus Schwabedissen
OrganisationQFINITY
EmailMarcusSchwabedissen@q-finity.de
  
Details of abstract  
Title of abstract Digital Transformation in the GCP Regulated World – More than just Technology
Abstract 

To reduce the overall costs of drugs, pharmaceutical companies need to look for innovations in the pharmaceutical value chain and research and development, especially clinical trials, which represent a great opportunity. It becomes more and more obvious that, in this space, digital transformations like wearables, health apps, and social media are being increasingly adopted by pharma companies and CROs alike, which will, in turn, improve the entire spectrum of patient recruitment, engagement and retention throughout the clinical trials study. In addition, new methods like virtual studies and technologies like artificial intelligence provide opportunities in this context and increase the speed of digital transformation. The presentation should provide an insight into what this development means for clinical trials and trigger discussions about the changed role of humans in future clinical trials and the importance of ethics and culture.

 

First learning objectiveUnderstand the current status of digital transformation in clinical trials
Second learning objectiveGet insight in future trends
Third learning objectiveRecognize value of ethics and culture as catalyst in the context of digital transformation
  
Presenter Details 
Name Marcus Schwabedissen 
OrganisationQFINITY
Job titleChief Operating Officer and Senior Executive Consultant